News Archive

Between now and 2020, we can expect to see a wave of innovation in pharma. But how will the coming drug launches fare in today’s challenging market? Consider these facts: the number of drugs per indication has risen by 37 percent since 2006, while the top company in an indication still commands at least half of the market. At the same time, restrictions to market access are rising in Europe, the United States, and emerging economies as advances in analytics and multichannel engagement open new opportunities to differentiate products.

Gilead Sciences, under intense investor pressure to do a significant M&A deal, may have found a target it likes. It is said to be evaluating United Therapeutics, although it finds itself in competition with GlaxoSmithKline and perhaps others.

The Evening Standard, citing unnamed sources, said that Gilead Sciences is considered the most likely candidate to win a bid for United Therapeutics. But the newspaper also said that GSK has Citi and Lazard helping it assess the United, a company founded in 1996 on a pulmonary arterial hypertension (PAH) drug that had been discarded by GSK.

WellDoc® and the American Association of Diabetes Educators (AADE) announce the collaborative launch of “The Diabetes Digital Health Learning Network” at the AADE17 conference. The goal of this Learning Network is to assist diabetes educators in gaining next-generation skills in using digital health therapeutics to improve clinical care and outcomes cost-effectively. “As a digital health leader, WellDoc is proud to launch ‘The Diabetes Digital Health Learning Network’ in collaboration with AADE to support its members who are on the front lines of diabetes care and management,” said WellDoc President and CEO Kevin McRaith. “This is a natural progression of our already-established partnership with AADE that began with our collaboration to incorporate The AADE Diabetes Education Curriculum into our FDA-cleared digital therapeutic platform, BlueStar®.”

As far as healthcare goes, Boston has historically focused on biotechnology, life sciences, and pharmaceuticals. Until a few years ago, digital health wasn’t a big talking point in the Boston healthcare scene. After a multilateral initiative launched in 2016, however, Boston wants to be regarded as a national leader in digital healthcare investment and activity.

With a focus on improving health, driving economic growth, and expanding the country’s research capacity, the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services is the largest public funder of biomedical research in the world. Because of NIH’s central role in supporting science, technology, and innovation, a better understanding of the agency’s footprint may be helpful to the technology-based economic development practitioner community. This edition of Useful Stats utilizes data from NIH’s Research Portfolio Online Reporting Tool (RePORT) and covers each year from 2007 to 2016. The data does not include projects funded by the American Recovery and Reinvestment Act of 2009.

Tuesday, September 26, 2017 9:00AM-5:00PM

Women of the Virginia bioscience community from across the state will lead this full day event offering examples of working together to build a stronger bioscience industry, stronger companies and institutions, stronger teams and networks, and stronger individuals.

New this year, we’re co-locating our event with The MedTech Conference powered by AdvaMed, to San Jose, CA!

Join us for this important program that dives into the changing landscape and the issues facing our pathway to greater innovation. This year’s theme is “Partnering for Breakthroughs in Pediatric Surgery and Care.”

Albeit small, Baltimore’s startup community is a thriving one. Just 45 minutes outside of the District, the city’s innovation scene is rich with opportunity and talent.

Maybe that’s why Baltimore is one of the most successful places working with Venture for America, a two-year salaried fellowship program that matches recent college grads with startups in 18 different cities.

Over the past year, Johns Hopkins University has played an integral role in bringing a nationwide program designed to boost small businesses to Baltimore and helping it flourish.

Today, program partners Goldman Sachs and Bloomberg Philanthropies announced a five-year, $10 million commitment to continue the program in Baltimore and named JHU the host site.

As Inova Health System prepares to open its new personalized health accelerator this fall, startups recently learned the terms of winning a spot there.

Inova plans to offer $75,000 in funding in exchange for 10 percent equity in early-stage companies selected to join the accelerator, Managing Director Hooks Johnston told an audience at a D.C. event last week. Johnston went on to say, according to Technical.ly DC, companies that make it through an individualized program for four or five months and can get $250,000 in third-party commitments can receive an Inova match.